1. Home
  2. TYGO vs STTK Comparison

TYGO vs STTK Comparison

Compare TYGO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$3.75

Market Cap

281.4M

Sector

Technology

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.42

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
STTK
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.4M
275.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TYGO
STTK
Price
$3.75
$6.42
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$6.00
$7.60
AVG Volume (30 Days)
425.7K
691.5K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
53.02
EPS
N/A
N/A
Revenue
$103,536,000.00
$1,000,000.00
Revenue This Year
$30.78
N/A
Revenue Next Year
$21.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
91.68
N/A
52 Week Low
$0.58
$0.69
52 Week High
$4.57
$6.81

Technical Indicators

Market Signals
Indicator
TYGO
STTK
Relative Strength Index (RSI) 49.70 67.18
Support Level $3.19 $5.75
Resistance Level $4.33 $6.81
Average True Range (ATR) 0.43 0.37
MACD -0.06 -0.04
Stochastic Oscillator 33.20 70.79

Price Performance

Historical Comparison
TYGO
STTK

About TYGO Tigo Energy Inc.

Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: